ELIXIRON

About ELIXIRON

Elixiron Immunotherapeutics, established in 2017 by co-founders Hung-Kai Kevin Chen, DawTsun Shih, Muh-Hwa Yang, and Cheng-Lung Ku, is a clinical-stage biotechnology firm concentrated on developing next-generation immunotherapies. The company operates with a mission to address unmet medical needs in cancer, neurodegenerative diseases, and inflammatory disorders through a translational medicine approach, leveraging clinical observations to guide drug discovery. With operations in San Francisco, Taipei, and Shanghai, Elixiron is strategically positioned to bridge research and development across North America and Asia.

The company was founded by a team with deep expertise in medicine and drug development. CEO Hung-Kai Kevin Chen previously served as senior vice president and chief medical officer at Eusol Biotech and was a drug hunter at GlaxoSmithKline. This background in both clinical-stage biotech and large pharmaceutical settings informs Elixiron's strategy of focusing on human translational studies to improve the likelihood of clinical success. The founding team also includes physician-scientist Dr. Muh-Hwa Yang and clinical immunologist Dr. Cheng-Lung Ku, whose translational work formed the company's foundation.

Elixiron's business model revolves around the research, development, and eventual commercialization of its therapeutic candidates. The company generates capital through private financing rounds and strategic grants to advance its pipeline. A significant milestone was the closing of a $27 million Series A-1 financing round in August 2021, co-led by Pangu Capital and Taiwania Capital, to progress its clinical-stage assets. The company has also received prestigious grants from the Alzheimer's Association's Part the Cloud program, some in partnership with Bill Gates, to fund trials for its lead Alzheimer's candidate.

The company's pipeline features several promising drug candidates. Its lead asset, Enrupatinib (EI-1071), is an orally available, small-molecule CSF1R inhibitor being developed for Alzheimer's disease and Tenosynovial Giant Cell Tumors. By inhibiting the CSF1R receptor, EI-1071 aims to modulate microglia-mediated neuroinflammation, a key factor in the progression of Alzheimer's. Another key candidate is Indemakitug (EI-001), a fully human antibody targeting IFN-γ for the treatment of vitiligo and other immunological disorders. Elixiron also has several immuno-oncology assets in earlier stages of development, focusing on counteracting immunosuppressive mechanisms in immunologically "cold" tumors that respond poorly to existing therapies.